These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2470986)
1. Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor. Ennis C; Granger SE; Middlefell VC; Philpot ME; Shepperson NB J Cardiovasc Pharmacol; 1989 Apr; 13(4):511-9. PubMed ID: 2470986 [TBL] [Abstract][Full Text] [Related]
2. Design of an antithrombotic-antihypertensive agent (Wy 27569). Synthesis and evaluation of a series of 2-heteroaryl-substituted dihydropyridines. Archibald JL; Bradley G; Opalko A; Ward TJ; White JC; Ennis C; Shepperson NB J Med Chem; 1990 Feb; 33(2):646-52. PubMed ID: 2299629 [TBL] [Abstract][Full Text] [Related]
3. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. Maguire ED; Wallis RB Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977 [TBL] [Abstract][Full Text] [Related]
5. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
6. Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. Chiabrando C; Broggini M; Castelli MG; Cozzi E; Castagnoli MN; Donelli MG; Garattini S; Giavazzi R; Fanelli R Cancer Res; 1987 Feb; 47(4):988-91. PubMed ID: 3100032 [TBL] [Abstract][Full Text] [Related]
7. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. FitzGerald GA; Brash AR; Oates JA; Pedersen AK J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181 [TBL] [Abstract][Full Text] [Related]
8. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses. Hardee MM; Moore JN; Hardee GE Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992 [TBL] [Abstract][Full Text] [Related]
9. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Ku EC; McPherson SE; Signor C; Chertock H; Cash WD Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803 [TBL] [Abstract][Full Text] [Related]
10. CGS 12970: a novel, long acting thromboxane synthetase inhibitor. Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197 [TBL] [Abstract][Full Text] [Related]
11. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord]. Morimoto K; Ikata T; Tounai T Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197 [TBL] [Abstract][Full Text] [Related]
12. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567 [TBL] [Abstract][Full Text] [Related]
13. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Deckmyn H; Van Houtte E; Verstraete M; Vermylen J Biochem Pharmacol; 1983 Sep; 32(18):2757-62. PubMed ID: 6578796 [TBL] [Abstract][Full Text] [Related]
14. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of type A GABA receptors by L-type calcium channel blockers. Das P; Bell-Horner CL; Huang RQ; Raut A; Gonzales EB; Chen ZL; Covey DF; Dillon GH Neuroscience; 2004; 124(1):195-206. PubMed ID: 14960351 [TBL] [Abstract][Full Text] [Related]
16. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben. Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066 [TBL] [Abstract][Full Text] [Related]
17. [(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors. Martinez GR; Walker KA; Hirschfeld DR; Maloney PJ; Yang DS; Rosenkranz RP J Med Chem; 1989 Apr; 32(4):890-7. PubMed ID: 2704033 [TBL] [Abstract][Full Text] [Related]
18. [Effect of dazoxiben on cerebrovascular resistance in rabbits]. Rui YC; Sun DX; Long K Zhongguo Yao Li Xue Bao; 1989 Jul; 10(4):342-5. PubMed ID: 2624120 [TBL] [Abstract][Full Text] [Related]
19. The effects of dauricine and verapamil as calcium channel blockers on the plasma concentration of 6-keto-prostaglandin F1 alpha and thromboxane B2 during cardiopulmonary bypass. Zhou JA; Fang WY; Wang C; Zhou JL; Guan HP Thorac Cardiovasc Surg; 1987 Jun; 35(3):172-5. PubMed ID: 2442837 [TBL] [Abstract][Full Text] [Related]
20. Imidazol-1-yl and pyridin-3-yl derivatives of 4-phenyl-1,4-dihydropyridines combining Ca2+ antagonism and thromboxane A2 synthase inhibition. Cozzi P; Carganico G; Fusar D; Grossoni M; Menichincheri M; Pinciroli V; Tonani R; Vaghi F; Salvati P J Med Chem; 1993 Oct; 36(20):2964-72. PubMed ID: 8411014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]